loading...
Distributed by Mapi Research Trust
Distributed by Mapi Research Trust
Developed in 2013 - version 6 currently available
A separate instrument for use in adolescent subjects is under development
Otsuka Pharmaceutical Development & Commercialization, Inc (USA)
Polycystic Kidney, Autosomal Dominant For more information on this rare disease, please consult the following link: Orphanet page
Cole JC, Krasa HB, Cheng R, et al. The Impact of Autosomal Dominant Polycystic Kidney Disease (ADPKD) on Patients' Health-Related Quality of Life (HRQoL): Developed of a Conceptual Framework. In: 16th International Society of Pharmacoeconomics and Outcomes Research (ISPOR); May 21-25, 2011; Baltimore, USA. Value in Health. 2011 May;14(3):A77 (Poster Abstract)
Cole JC, Oberdhan D, Cheng R, et al. Patient-Experienced Impact from Autosomal Dominant Polycystic Kidney Disease (ADPKD): Summary of Burden Noted in North American, European, and Japanese Focus Groups. In: 48th European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress; June 23-26, 2011; Prague (Poster Abstract)
Oberdhan D, Chapman AB, Davison SN, et al. Patient-reported Pain in Autosomal Dominant Polycystic Kidney Disease (ADPKD): Initial Concepts Based on Patient Focus Group Discussions. American Society of Nephrology - Kidney Week. 2013;SA-PO283:692A (Poster Abstract)
Cheng R, Oberdhan D, Krasa H, Cole JC. Patient-reported Pain in Autosomal Dominant Polycystic Kidney Disease (ADPKD): Concept Stability Between Europe and United States (US) Focus Groups. ISOQOL 2013. Poster.
Palsgrove AC, Guay-Woodford LM, Cheng R, et al. Burden of Autosomal Dominant Polycystic Kidney Disease (ADPKD): Effects on the Daily Lives of Patients and Their Caregivers. American Journal of Kidney Diseases. 2014 May;63(5):B86 (Poster Abstract)
Oberdhan D, Palsgrove A, Cole J, Blais J, Cheng R. Patient Experience with Pain Related to Autosomal Dominant Polycystic Kidney Disease (ADPKD). World Congress of Nephrology, 2015
Otsuka Pharmaceutical Development & Commercialization, Inc (USA)
Otsuka Pharmaceutical Development & Commercialization, Inc.
2440 Research Boulevard
Rockville, MD 20850
USA
Phone: +1-240-683-3517 |
Fax: +1-301-721-7517 |
Contact person:
Dorothee Oberdhan, MS
Senior Manager, HEOR and Outcomes Management
E-mail: dorothee.oberdhan@otsuka-us.com
Mapi Research Trust
PROVIDE™
27 rue de la Villette
69003 Lyon
France
Phone: +33 (0)4 72 13 66 66
You may access available translations of the questionnaire directly (see tutorial). Should you not see the Download button, please contact us.
All requests have to be submitted through our online request management:
Examination copies can only be used for the limited purpose of examining the suitability of the Questionnaire for subsequent research and/or clinical use, and cannot be used in research or in clinical practice or distributed to others.
You are not authorized to modify, retype, translate, copy or otherwise duplicate the Questionnaire except with the further and prior written permission of Mapi Research Trust / the developers / copyright holders / distributors.
The listed translations may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study. This list is subject to constant changes, therefore please check the status of translations with Mapi Research Trust / the developers / copyright holders / distributors.
The author has selected Mapi/ICON Language Services as exclusive linguistic validation company to ensure the production of harmonized and consistent language versions.
For additional information on available translations of this instrument, or for a project involving new languages, please submit a request (tutorials available on our FAQs).
If you wish to translate the questionnaire:
Access to advanced descriptions of Clinical Outcome Assessments (COAs)